KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Common Equity (2016 - 2025)

Gilead Sciences (GILD) has disclosed Common Equity for 17 consecutive years, with $22.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 17.96% year-over-year to $22.7 billion, compared with a TTM value of $22.7 billion through Dec 2025, up 17.96%, and an annual FY2025 reading of $22.7 billion, up 17.96% over the prior year.
  • Common Equity was $22.7 billion for Q4 2025 at Gilead Sciences, up from $19.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $22.7 billion in Q4 2023 and bottomed at $17.5 billion in Q1 2024.
  • Average Common Equity over 5 years is $20.3 billion, with a median of $20.2 billion recorded in 2022.
  • The sharpest move saw Common Equity increased 22.9% in 2021, then dropped 17.32% in 2024.
  • Year by year, Common Equity stood at $21.1 billion in 2021, then increased by 0.69% to $21.2 billion in 2022, then grew by 7.26% to $22.7 billion in 2023, then decreased by 15.4% to $19.2 billion in 2024, then grew by 17.96% to $22.7 billion in 2025.
  • Business Quant data shows Common Equity for GILD at $22.7 billion in Q4 2025, $19.6 billion in Q2 2025, and $19.1 billion in Q1 2025.